French Professional Services Stock News

ENXTPA:EN
ENXTPA:ENConstruction

A Look At Bouygues (ENXTPA:EN) Valuation After New Colas Interstate 10 Contract Win

Bouygues (ENXTPA:EN) is back in focus after its road subsidiary Colas secured a major contract on the Interstate 10 highway in California, which underlines the group’s international reach in core construction activities. See our latest analysis for Bouygues. Bouygues’ latest contract win comes after a run of corporate updates, including full year 2025 results, new 2026 earnings guidance and a proposed higher dividend. The shares are now at €49.16 and show strong 1 year and 5 year total...
ENXTPA:ENGI
ENXTPA:ENGIIntegrated Utilities

Is It Too Late To Consider Engie (ENXTPA:ENGI) After A 72% One-Year Rally?

If you are wondering whether Engie’s current share price still offers value after a strong run, you are not alone. This article is built to help you think that through clearly. Engie’s stock last closed at €27.04, with returns of 0.1% over 7 days, 5.2% over 30 days, 17.7% year to date and 72.3% over 1 year, while the 3 year and 5 year returns sit at 151.6% and 227.8% respectively. Recent coverage has focused on Engie’s role as a major utilities player in France and Europe, including ongoing...
ENXTPA:SAN
ENXTPA:SANPharmaceuticals

How New CHMP Opinions on Dupixent and Acoziborole Will Impact Sanofi (ENXTPA:SAN) Investors

In late February 2026, Sanofi and Regeneron reported that the European Medicines Agency’s CHMP issued positive opinions for Dupixent in young children with chronic spontaneous urticaria and for Acoziborole Winthrop as a single-dose oral treatment for gambiense sleeping sickness, with final EU decisions expected in the months that followed. These CHMP endorsements highlight how Sanofi’s immunology and neglected tropical disease programs may broaden its treatment footprint across both...
ENXTPA:AM
ENXTPA:AMAerospace & Defense

Assessing Dassault Aviation (ENXTPA:AM) Valuation After Earnings Beat Guidance Dividend Hike And Share Cancellation

Dassault Aviation société anonyme (ENXTPA:AM) has attracted fresh attention after reporting full year 2025 earnings, issuing 2026 sales guidance toward about €8.5b, and outlining a higher proposed dividend alongside a share cancellation. See our latest analysis for Dassault Aviation société anonyme. Those results and the 2026 sales guidance land after a strong run in the shares, with a 27.36% 3 month share price return and a 289.46% 5 year total shareholder return, pointing to building...
ENXTPA:OR
ENXTPA:ORPersonal Products

A Look At L'Oréal (ENXTPA:OR) Valuation After New Carbon Capture Packaging Partnership

L'Oréal (ENXTPA:OR) has drawn fresh attention from investors after announcing a multi year partnership with clean tech firm Dioxycle to turn captured carbon emissions into sustainable packaging materials via carbon electrolysis. See our latest analysis for L'Oréal. Despite a steady stream of sustainability, retail and product launches, L'Oréal's 30 day share price return of a 7.87% decline and modest 1 year total shareholder return of 3.76% suggest momentum has cooled recently compared with...
ENXTPA:KER
ENXTPA:KERLuxury

Assessing Kering (ENXTPA:KER) Valuation After Wide Reorganization And New Leadership Appointments

Kering (ENXTPA:KER) has announced a wide reorganization, creating new Industry and Client centers of excellence and installing seasoned leaders to oversee production, supply chains, marketing, and client focused functions across its luxury Houses. See our latest analysis for Kering. At a share price of €262.65, Kering has seen a 3.1% 1 day and 3.3% 7 day share price return, yet its year to date share price return of 13.77% decline and 3 year total shareholder return of 49.01% decline suggest...
ENXTPA:IMDA
ENXTPA:IMDAREITs

Immobiliere Dassault FY 2025 EPS Jump Challenges Long Term Earnings Decline Narrative

Immobiliere Dassault (ENXTPA:IMDA) has released its FY 2025 numbers with first half revenue of €17.1 million and basic EPS of €2.83, setting the tone against a backdrop of longer term earnings pressure. The company has seen revenue move from €15.8 million in the first half of 2024 to €14.6 million in the second half of 2024 and then to €17.1 million in the latest period, while basic EPS shifted from €1.46 to €2.53 and now €2.83. Investors are left to weigh these headline figures against a...
ENXTPA:TTE
ENXTPA:TTEOil and Gas

TotalEnergies Battery Deal With Allianz Highlights Evolving Energy Transition Story

TotalEnergies (ENXTPA:TTE) agreed to sell a 50% stake in 11 battery storage projects in Germany to Allianz Global Investors. The portfolio represents 789 MW and 1,628 MWh of storage capacity, with an implied investment of €500 million. Most projects will use next generation battery technology supplied by TotalEnergies subsidiary Saft. TotalEnergies will continue to operate the assets while Allianz Global Investors takes a co-ownership role. For you as an investor, this move highlights how...
ENXTPA:CS
ENXTPA:CSInsurance

How AXA’s 2026 Buyback, Higher Dividend and Earnings Jump At AXA (ENXTPA:CS) Has Changed Its Investment Story

AXA SA has already announced for 2026 a new share repurchase program of up to €1,250 million, authorized by its Board, alongside a higher annual dividend of €2.32 per share and reported past-year net income of €9.80 billion versus €7.89 billion previously. This combination of a sizeable buyback, increased cash returns, and higher net income signals a strong focus on rewarding shareholders and underscores management’s confidence in the business. We’ll now examine how AXA’s sizeable share...
ENXTPA:RMS
ENXTPA:RMSLuxury

A Look At Hermès (ENXTPA:RMS) Valuation As Shares Lag Recent Fair Value Estimates

Returns snapshot and recent stock performance Hermès International Société en commandite par actions (ENXTPA:RMS) has delivered a 1 day return of 2.31% and 7 day return of 2.66%, while the share price is down about 5.21% over the past month. Over the past 3 months the stock shows a return of about 8.50%, with year to date performance around 7.41% lower. On a 1 year basis, the total return stands near 20.31% lower, compared with a 3 year total return of 15.58% and a 5 year total return a...
ENXTPA:SW
ENXTPA:SWHospitality

Is Sodexo (ENXTPA:SW) Pricing Make Sense After A 38.3% One Year Share Price Fall

If you are wondering whether Sodexo shares are offering fair value today, this article will walk through what the current price might be implying about the company. Sodexo's share price closed at €44.42, with returns of a 1.6% decline over the last 7 days, a 1.7% decline over 30 days, a 3.4% gain year to date, and a 38.3% decline over the past year. This raises questions about how the market is currently pricing its prospects and risks. Recent news around Sodexo has focused on its role as a...
ENXTPA:RNO
ENXTPA:RNOAuto

Renault futuREady Plan Tests Valuation Discount With 36-Model Expansion

Renault has launched a new group plan called "futuREady" that targets 36 new model launches by 2030. The plan puts more weight on electrification, product development and partnerships across Renault’s ecosystem. A key element is a stronger push beyond Renault’s traditional European strongholds to capture more international growth. For investors watching ENXTPA:RNO, this fresh plan lands at a time when the shares trade around €28.17 and have faced pressure, with a 1 year return of a 38.1%...
ENXTPA:VU
ENXTPA:VUElectronic

Assessing Vusion (ENXTPA:VU) After 2025 Results 2026 Guidance And Qualcomm AI Retail Partnership

Vusion (ENXTPA:VU) has been in focus after reporting 2025 sales of €1,472 million with net income of €84.2 million, issuing 2026 earnings guidance, and outlining an AI retail partnership with Qualcomm. See our latest analysis for Vusion. Despite the recent earnings, 2026 guidance and Qualcomm AI retail partnership, Vusion’s 30 day share price return of 12.12% and year to date share price return of 46.94% suggest momentum has been weak, even though the 5 year total shareholder return of...
ENXTPA:IPN
ENXTPA:IPNPharmaceuticals

Assessing Ipsen (ENXTPA:IPN) Valuation After Strong Recent Share Price Momentum

Why Ipsen Stock Is On Investors’ Radar Ipsen (ENXTPA:IPN) has drawn attention after a solid recent share price run, with the stock showing positive returns over the month and past 3 months, prompting closer inspection of its fundamentals. See our latest analysis for Ipsen. The latest move to €157.1 comes after a 15.43% 1 month share price return and a 29.30% 3 month share price return, set against a 46.21% 1 year total shareholder return and 146.66% 5 year total shareholder return that signal...
ENXTPA:SCHP
ENXTPA:SCHPCommercial Services

Séché Environnement (ENXTPA:SCHP) Margin Compression Tests Bullish Growth Narratives

Séché Environnement (ENXTPA:SCHP) has just reported its FY 2025 first half with revenue of €612.9 million and basic EPS of €2.05, setting the tone for how investors assess the latest leg of its earnings story. Over recent periods, revenue has moved from €540.5 million and EPS of €1.02 in 1H 2024 to €649.9 million and EPS of €3.57 in 2H 2024. Trailing twelve month EPS for 1H 2025 sits at €5.61 on revenue of about €1.3 billion, which frames today’s numbers against a much larger revenue base...
ENXTPA:DBV
ENXTPA:DBVBiotechs

DBV Technologies (ENXTPA:DBV) Valuation After Positive Phase 3 Peanut Patch Results

DBV Technologies (ENXTPA:DBV) recently reported additional positive data from its Phase 3 VITESSE trial of the VIASKIN Peanut Patch in peanut allergic children, with the study meeting its primary endpoint and showing a statistically significant treatment effect. See our latest analysis for DBV Technologies. The latest clinical update appears to be feeding into stronger momentum, with a 7.3% 1 day share price return and a 36.95% 90 day share price return at €4.04, alongside a very large 1 year...
ENXTPA:STMPA
ENXTPA:STMPASemiconductor

Assessing STMicroelectronics’ Valuation As New AI Photonics And UWB Chips Expand Its Data Center Role

Why this new AI and UWB push matters for STMicroelectronics STMicroelectronics (ENXTPA:STMPA) has moved into high-volume production of its silicon photonics PIC100 platform for AI data centers while also unveiling a new ultra-wideband chip family for precise localization in cars and connected devices. For you as an investor, these parallel moves bring the focus squarely onto how much value the market assigns to STMicroelectronics’ role in AI infrastructure and intelligent hardware, rather...
ENXTPA:CLARI
ENXTPA:CLARIHealthcare

Why Clariane (ENXTPA:CLARI) Is Down 5.9% After Returning To Profitability On Flattish Sales - And What's Next

In February 2026, Clariane SE reported its full-year 2025 results, with sales of €5,310.3 million and net income of €1.6 million, reversing the prior year’s net loss. This shift back to profitability, achieved on only a small increase in sales from €5,281.8 million, highlights the impact of cost discipline and operational improvements. With Clariane’s return to profitability now on record, we’ll examine how this development reshapes the company’s investment narrative and outlook. Capitalize...
ENXTPA:VIE
ENXTPA:VIEIntegrated Utilities

Veolia Deepens US Waste And Water Role With Long Term Contract Focus

Veolia Environnement announced a new US hazardous waste acquisition, expanding its presence in the North American market. The company is extending its PFAS treatment capabilities across North America to address growing water quality challenges. Veolia and the National Association of Water Companies published a policy white paper calling for large scale water infrastructure investment in the US. Veolia Environnement (ENXTPA:VIE), trading at €32.4, has seen its share price return 7.5% year to...
ENXTPA:ERF
ENXTPA:ERFLife Sciences

Assessing Eurofins Scientific (ENXTPA:ERF) Valuation After Recent Share Price Pullback

Eurofins Scientific share performance snapshot Eurofins Scientific (ENXTPA:ERF) has drawn investor attention after recent share price moves, with the stock showing mixed short term performance and stronger longer term returns that contrast with some weaker multi year results. See our latest analysis for Eurofins Scientific. At a share price of €63.52, Eurofins Scientific has seen a 6.6% decline in its 30 day share price return after a recent pullback. Its 1 year total shareholder return of...
ENXTPA:GDS
ENXTPA:GDSHealthcare

Ramsay Générale De Santé (ENXTPA:GDS) Valuation Check After Half Year Sales Growth And Narrowing Net Loss

Ramsay Générale de Santé (ENXTPA:GDS) has released half year results to December 31, 2025, reporting sales of €2,589.1 million and a net loss of €34.9 million, both changing compared with a year earlier. See our latest analysis for Ramsay Générale de Santé. The half year update comes after a period where the share price has shown mixed momentum, with a 15.22% 90 day share price return and a 13.49% year to date share price return, yet a 3 year total shareholder return of a 45.36% decline. If...
ENXTPA:VK
ENXTPA:VKEnergy Services

Assessing Vallourec (ENXTPA:VK) Valuation After Weaker 2025 Earnings Results

Earnings event puts Vallourec (ENXTPA:VK) in focus Vallourec (ENXTPA:VK) is back on investors’ radar after reporting fourth quarter and full year 2025 results, with both sales and net income below the previous year’s levels, raising fresh questions about the earnings profile. See our latest analysis for Vallourec. The €19.505 share price sits against a 30 day share price return of 5.32% and a 90 day share price return of 25.68%. The 1 year total shareholder return of 30.57% and 5 year total...
ENXTPA:OPM
ENXTPA:OPMAuto Components

OPmobility (ENXTPA:OPM) Lifts Dividend And Targets Higher Margins Is Its Capital Allocation Shifting?

In February 2026, OPmobility reported its 2025 results, with sales of €10,216 million, net income of €185 million, and basic earnings per share of €1.30, while announcing a higher annual dividend of €0.49 per share payable on April 30, 2026. Alongside these results, the company set an objective for 2026 to improve both operating margin and net result Group share compared with 2025, signalling a focus on profitability despite slightly lower sales. We’ll now examine how OPmobility’s higher...
ENXTPA:SAN
ENXTPA:SANPharmaceuticals

Sanofi Regulatory Wins Highlight Dupixent Growth And Public Health Reach

Sanofi (ENXTPA:SAN) received FDA approval in the US for Dupixent as the first designated treatment for allergic fungal rhinosinusitis. EU regulators issued a positive opinion for Dupixent in young children with chronic spontaneous urticaria. The EU also gave a positive opinion for Acoziborole Winthrop, a single dose oral treatment for sleeping sickness in adults and adolescents. For Sanofi, these decisions touch both its core immunology franchise and its long running work in neglected...